AM
AMG.XETRA Amgen Inc.
- Market cap
- EUR 226B
- P/E
- 28.2x
- P/B
- 17.88x
- ROE
- 76.7%
- Dividend yield
- 2.12%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AMG.XETRA undervalued?
Graham numberThe Graham number of Amgen Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Amgen Inc. fundamental analysis
No fundamental analysis for Amgen Inc. yet.
Amgen Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which re…
Full company profileAmgen Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Amgen Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 23.0B | 22.8B | 23.7B | 23.4B | 25.4B | 26.0B | 26.3B | 28.2B | 33.4B | 36.8B | 39.0B |
| Gross Profit | 18.8B | 18.8B | 19.6B | 19.0B | 19.3B | 19.5B | 19.9B | 19.8B | 20.6B | 30.3B | 29.0B |
| Operating Income | 9.79B | 9.97B | 10.3B | 9.67B | 5.79B | 6.01B | 5.34B | 7.90B | 7.26B | 14.9B | 14.5B |
| EBITDA | 11.9B | 12.9B | 12.9B | 12.6B | 12.9B | 12.5B | 12.2B | 14.8B | 13.4B | 16.9B | 17.9B |
| Net Income | 7.72B | 1.98B | 8.39B | 7.84B | 7.26B | 5.89B | 6.55B | 6.72B | 4.09B | 7.71B | 10.9B |
| EPS | 10 | 2.69 | 13 | 13 | 12 | 10 | 12 | 12 | 7.56 | 14 | 20 |
| Balance Sheet | |||||||||||
| Total Assets | 77.6B | 80.0B | 66.4B | 59.7B | 62.9B | 61.2B | 65.1B | 97.2B | 91.8B | 90.6B | 94.7B |
| Total Liabilities | 47.8B | 54.7B | 53.9B | 50.0B | 53.5B | 54.5B | 61.5B | 90.9B | 86.0B | 81.9B | 80.6B |
| Shareholders' Equity | 29.9B | 25.2B | 12.5B | 9.67B | 9.41B | 6.70B | 3.66B | 6.23B | 5.88B | 8.66B | 14.2B |
| Cash & Short-term Investments | 38.1B | 41.7B | 29.3B | 8.91B | 10.6B | 8.04B | 9.31B | 10.9B | 12.0B | 9.13B | 13.0B |
| Total Debt | 34.6B | 35.3B | 33.9B | 29.9B | 33.0B | 33.3B | 38.9B | 64.6B | 60.1B | 54.6B | 53.3B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 10.4B | 11.2B | 11.3B | 9.15B | 10.5B | 9.26B | 9.72B | 8.47B | 11.5B | 9.96B | 13.9B |
| Capital Expenditure | 837M | 664M | 738M | 618M | 608M | 880M | 936M | 1.11B | 1.10B | 1.86B | 2.41B |
| Free Cash Flow | 9.52B | 10.5B | 10.6B | 8.53B | 9.89B | 8.38B | 8.79B | 7.36B | 10.4B | 8.10B | 11.5B |
| Ratios | |||||||||||
| ROE | 25.8% | 7.8% | 67.2% | 81.1% | 77.2% | 88.0% | 179.0% | 107.8% | 69.6% | 89.1% | 76.7% |
| ROA | 9.9% | 2.5% | 12.6% | 13.1% | 11.5% | 9.6% | 10.1% | 6.9% | 4.5% | 8.5% | 11.5% |
| Net Profit Margin | 33.6% | 8.7% | 35.3% | 33.6% | 28.6% | 22.7% | 24.9% | 23.8% | 12.2% | 21.0% | 27.8% |
| Debt to Equity | 1.16x | 1.40x | 2.71x | 3.09x | 3.51x | 4.97x | 10.64x | 10.37x | 10.23x | 6.31x | 3.76x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Amgen Inc. dividends
- Dividend yield
- 2.12%
- Forward dividend
- 8.99 EUR
- Payout ratio
- 66.4%
- Ex-dividend date
- Nov 20, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 5.12B | 9.45 | 66.4% |
| 2024 | USD 4.83B | 8.93 | 118.1% |
| 2023 | EUR 4.56B | 8.47 | 67.8% |
| 2022 | USD 4.20B | 7.76 | 64.0% |
| 2021 | EUR 4.01B | 7.00 | 68.1% |
| 2020 | EUR 3.76B | 6.36 | 51.7% |
| 2019 | EUR 3.51B | 5.76 | 44.7% |
| 2018 | EUR 3.51B | 5.27 | 41.8% |
| 2017 | EUR 3.37B | 4.58 | 170.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Nov 22, 1999.
Who owns Amgen Inc.
- Insiders 0.23%
- Institutions 85.02%
- Public & others 14.75%
- Shares outstanding 541M
- Free float 540M
Amgen Inc. company profile
- Company name
- Amgen Inc.
- Ticker
- AMG.XETRA
- Exchange
- XETRA Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 31,500
- Fiscal year end
- December
- Address
- One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799
- Phone
- 805 447 1000
- Website
- amgen.com
About Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he
Amgen Inc. management
2- Mr. Robert A. BradwayChairman & CEO · born 1963
- Mr. Murdo GordonExecutive Vice President of Global Markets and Policy · born 1967